ClinicalTrials.gov record
Terminated Phase 3 Interventional

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

ClinicalTrials.gov ID: NCT05329545

Public ClinicalTrials.gov record NCT05329545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)

Study identification

NCT ID
NCT05329545
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mersana Therapeutics
Industry
Enrollment
20 participants

Conditions and interventions

Interventions

  • Placebo Other
  • Upifitimab rilsodotin Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 22, 2022
Primary completion
Sep 28, 2023
Completion
Sep 28, 2023
Last update posted
Oct 25, 2023

2022 – 2023

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
HonorHealth Research Institute - HonorHealth VGPCC Biltmore Phoenix Arizona 85016
The University of Arizona Cancer Center Tucson Arizona 85719
University of California Los Angeles, Gynecologic Oncology Clinic Los Angeles California 90095
University of California, Irvine Medical Center Orange California 92868
Sarasota Memorial Hospital Sarasota Florida 34239
University of Chicago Medical Center Chicago Illinois 60637
WK Physicians Shreveport Louisiana 71103
Karmanos Cancer Institute - Detroit Detroit Michigan 48201
Billings Clinic Billings Montana 59101
Methodist Hospital Omaha Nebraska 68114
Women's Cancer Center of Nevada Las Vegas Nevada 89106
Center of Hope Reno Nevada 89433
University of New Mexico Cancer Center Albuquerque New Mexico 87106
Southwest Women's Oncology Albuquerque New Mexico 87109
University Hospitals Cleveland Medical Center, Seidman Cancer Center Cleveland Ohio 44106
Kettering Health Cancer Center Kettering Ohio 45429
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Willamette Valley Cancer Institute and Research Center Eugene Oregon 97401
Legacy Good Samaritan Medical Center - Legacy Medical Group - Gynecologic Oncology Portland Oregon 97210
Asplundh Cancer Pavilion Willow Grove Pennsylvania 19090
Sanford Gynecologic Oncology Sioux Falls South Dakota 57104
Avera McKennan d/b/a Avera Research Institute Sioux Falls South Dakota 57105
Texas Oncology P.A. - Austin Austin Texas 78745
Texas Oncology - DFWW Bedford Texas 76022
Texas Oncology - Tyler Tyler Texas 75702
VCU Massey Cancer Center Richmond Virginia 23291
University of Wisconsin Clinical Science Center Madison Wisconsin 53792
Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05329545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 25, 2023 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05329545 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →